Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Location Directory

Clinical trials in Houston, Texas

This page shows live ClinicalTrials.gov search results for Houston, Texas, with direct links to official study records plus on-page filtering and sorting for broad location searches.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 7:13 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
22526
Shown on this page
12
Current sort
Recently updated
Location scope
Houston, TX
Filters apply within this location only.

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

Filter and sort this location

These controls apply only within Houston, Texas. Default order is Recently updated. Use recruitment status if you want to focus on actively recruiting studies in this location.

Reset location filters
Clear filters
Showing 577–588 of 22,526 matching trials in Houston, TX.
Live ClinicalTrials.gov results.
Local directory summary panels are hidden while filters are applied so the page stays focused on the filtered live results.

Institutions in Houston

Campus pages list official records that name the campus as a study site. Listed in directory order, not ranked.

Live official records

Open in full search
Active, not recruiting Not applicable Interventional

A Clinical Study to Evaluate the Safety and Efficacy of the FloStent in Men With Benign Prostatic Hyperplasia Symptoms

NCT06849258
View directory record Official record
Conditions
Benign Prostatic Hyperplasia
Interventions
FloStent, Sham (Control)
Device
Lead sponsor
Rivermark Medical
Industry
Eligibility
45 Years and older · Male only
Enrollment
215 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2032
U.S. locations
19
States / cities
Bakersfield, California • Beverly Hills, California • La Mesa, California + 15 more
Source: ClinicalTrials.gov public record
Updated Nov 9, 2026 · Synced Nov 15, 2026, 7:13 AM EST
Recruiting Phase 2 Interventional

Study of Targeted Therapies for the Treatment of Adult Participants With Active Psoriatic Arthritis

NCT06865105
View directory record Official record
Conditions
Psoriatic Arthritis
Interventions
Lutikizumab, Risankizumab, ABBV-701, ABBV-547
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
19
States / cities
Huntington Beach, California • Avon Park, Florida • Clearwater, Florida + 16 more
Source: ClinicalTrials.gov public record
Updated Nov 9, 2026 · Synced Nov 15, 2026, 7:13 AM EST
Active, not recruiting Phase 1Phase 2 Interventional

A Study to Evaluate the Safety, Pharmacokinetics and Preliminary Anti-Tumor Activity of Englumafusp Alfa in Combination With Obinutuzumab and in Combination With Glofitamab Following a Pre-Treatment Dose of Obinutuzumab in Participants With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma

NCT04077723
View directory record Official record
Conditions
Lymphoma, Non-Hodgkin
Interventions
Englumafusp alfa, Obinutuzumab, Glofitamab, Tocilizumab
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
498 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
4
States / cities
Pasadena, California • San Francisco, California • St Louis, Missouri + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 9, 2026 · Synced Nov 15, 2026, 7:13 AM EST
Recruiting Phase 2 Interventional

A Phase IIb Dose-ranging Study to Assess the Efficacy and Safety of GIA632 in Participants With Non-segmental Vitiligo

NCT07431177
View directory record Official record
Conditions
Non-segmental Vitiligo
Interventions
GIA632, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 99 Years
Enrollment
210 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
24
States / cities
Birmingham, Alabama • Fountain Valley, California • San Diego, California + 21 more
Source: ClinicalTrials.gov public record
Updated Nov 9, 2026 · Synced Nov 15, 2026, 7:13 AM EST
Terminated Phase 1 Interventional

A Study to Evaluate the Safety and Efficacy of OPB-101 in Platinum-resistant Ovarian Cancer

NCT07030907
View directory record Official record
Conditions
Ovarian Cancer Recurrent, Ovarian Cancer, Platinum Resistant Ovarian Cancer
Interventions
OPB-101
Biological
Lead sponsor
Outpace Bio, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
4
States / cities
Detroit, Michigan • Minneapolis, Minnesota • Buffalo, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 9, 2026 · Synced Nov 15, 2026, 7:13 AM EST
Active, not recruiting Phase 1 Interventional

Actinium Therapy for Late-stage Aggressive Sarcomas

NCT07156565
View directory record Official record
Conditions
Advanced Soft Tissue Sarcoma
Interventions
[Ac 225]RTX-2358, [Cu64]LNTH-1363S
Drug · Diagnostic Test
Lead sponsor
Ratio Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2032
U.S. locations
5
States / cities
Los Angeles, California • Rochester, Minnesota • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 9, 2026 · Synced Nov 15, 2026, 7:13 AM EST
Not yet recruiting No phase listed Observational

PureSee EDOF Versus ZCB00 Monofocal IOLs in Mild-to-Moderate Glaucoma

NCT07924215
View directory record Official record
Conditions
Primary Open-Angle Glaucoma
Interventions
TECNIS PureSee Intraocular Lens, TECNIS ZCB00 Monofocal Intraocular Lens
Device
Lead sponsor
Mann Eye Institute
Other
Eligibility
45 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 9, 2026 · Synced Nov 15, 2026, 7:13 AM EST
Recruiting Phase 4 Interventional

Asciminib Roll-over Study

NCT04877522
View directory record Official record
Conditions
Chronic Myelogenous Leukemia, Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Interventions
Asciminib single agent, Imatinib, Nilotinib, Bosutinib, Dasatinib, Asciminib single agent pediatric formulation
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
7 Years to 100 Years
Enrollment
347 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2030
U.S. locations
9
States / cities
Ann Arbor, Michigan • St Louis, Missouri • New York, New York + 6 more
Source: ClinicalTrials.gov public record
Updated Nov 9, 2026 · Synced Nov 15, 2026, 7:13 AM EST
Completed Phase 3 Interventional Results available

A Study of Androgen Annihilation in High-Risk Biochemically Relapsed Prostate Cancer

NCT03009981
View directory record Official record
Conditions
Prostate Cancer
Interventions
Apalutamide, LHRH Analogue, Abiraterone Acetate, Prednisone
Drug
Lead sponsor
Alliance Foundation Trials, LLC.
Other
Eligibility
18 Years and older · Male only
Enrollment
503 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2025
U.S. locations
69
States / cities
Phoenix, Arizona • Chula Vista, California • Duarte, California + 58 more
Source: ClinicalTrials.gov public record
Updated Nov 9, 2026 · Synced Nov 15, 2026, 7:13 AM EST
Recruiting Phase 3 Interventional

A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight Without Type 2 Diabetes

NCT07351045
View directory record Official record
Conditions
Obesity or Overweight
Interventions
Placebo, Enicepatide
Combination Product
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
2,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
44
States / cities
Anniston, Alabama • Birmingham, Alabama • Tucson, Arizona + 37 more
Source: ClinicalTrials.gov public record
Updated Nov 9, 2026 · Synced Nov 15, 2026, 7:13 AM EST
Recruiting Phase 2 Interventional

A Study of Lirafugratinib in Non-CCA Solid Tumors With FGFR2 Fusion or Rearrangement

NCT07359820
View directory record Official record
Conditions
FGFR2 Gene Fusion/Rearrangement, Other Solid Tumors, Adult
Interventions
Lirafugratinib
Drug
Lead sponsor
Elevar Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
8
States / cities
Phoenix, Arizona • Jacksonville, Florida • Tampa, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Nov 9, 2026 · Synced Nov 15, 2026, 7:13 AM EST
Recruiting Not applicable Interventional Accepts healthy volunteers

Adapting and Assessing the Feasibility of a Telehealth Diabetes Prevention Program for Hispanic Adolescents

NCT06943001
View directory record Official record
Conditions
Obesity and Type 2 Diabetes
Interventions
Fit24+
Behavioral
Lead sponsor
Baylor College of Medicine
Other
Eligibility
14 Years to 16 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 9, 2026 · Synced Nov 15, 2026, 7:13 AM EST